Țica Ovidiu, Țica Otilia
Department of Morphological Disciplines, Faculty of Medicine and Pharmacy,410073 Oradea, Romania.
Pathology Department, Emergency County Clinical Hospital of Bihor, 410165 Oradea, Romania.
Diagnostics (Basel). 2025 Jul 17;15(14):1807. doi: 10.3390/diagnostics15141807.
Heart failure (HF) is a global health burden characterized by high morbidity and mortality, necessitating advancements in diagnostic and therapeutic approaches. Molecular diagnostics, encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenetics, offer unprecedented insights into HF pathogenesis, aiding early diagnosis, risk stratification, and personalized management. This state-of-the-art review critically examines recent developments in molecular diagnostics in HF, evaluates their translational potential, and highlights key challenges in clinical implementation. Emerging tools such as liquid biopsy, multi-omics integration, and artificial intelligence (AI)-driven platforms are explored. We propose strategies to enhance clinical translation, equity in access, and utility in guiding treatment, thereby advancing precision cardiovascular medicine.
心力衰竭（HF）是一种全球健康负担，其特征是高发病率和高死亡率，这就需要在诊断和治疗方法上取得进展。分子诊断学涵盖基因组学、转录组学、蛋白质组学、代谢组学和表观遗传学，为心力衰竭的发病机制提供了前所未有的见解，有助于早期诊断、风险分层和个性化管理。这篇前沿综述批判性地审视了心力衰竭分子诊断学的最新进展，评估了它们的转化潜力，并强调了临床应用中的关键挑战。文中还探讨了诸如液体活检、多组学整合和人工智能（AI）驱动平台等新兴工具。我们提出了增强临床转化、公平获取以及指导治疗实用性的策略，从而推动精准心血管医学的发展。
